Fusion Antibodies Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
FAB
- Share Price
-
$0.07
- (As of Friday Closing)
Fusion Antibodies General Information
Description
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
Contact Information
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Stock Exchange
LON
Primary Office
- 1 Springbank Road
- Dunmurry
- Belfast BT17 0QL
- Northern Ireland, United Kingdom
+44 020 0000 0000
Fusion Antibodies Timeline
Fusion Antibodies Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.08 | $0.06 - $0.85 | $4.73M | 59.5M | 1.04M | -$0.12 |
Fusion Antibodies Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 |
|---|---|---|---|---|
| EV | 11,439 | 11,439 | 18,040 | 51,493 |
| Revenue | 3,493 | 3,493 | 6,555 | 5,435 |
| EBITDA | (2,940) | (2,940) | (784) | (698) |
| Net Income | (3,126) | (3,126) | (1,639) | (3,783) |
| Total Assets | 2,554 | 2,554 | 6,456 | 8,013 |
| Total Debt | 93 | 93 | 91 | 316 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Fusion Antibodies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Fusion Antibodies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Fusion Antibodies Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antib
Biotechnology
Belfast, United Kingdom
55
As of 2022
000.00
000000000
000.00
000000
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu
0000000000000
Redcar and Cleveland, United Kingdom
0
As of 0000
00.000
0000000000
00000
e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
South San Francisco, CA
000
As of 0000
00000
00000000
00000
Add Comparison
Fusion Antibodies Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Absolute Antibody | Private Equity-Backed | Redcar and Cleveland, United Kingdom | 0 | 00.000 | 0000000000 | |
| 00000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000 | Formerly VC-backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
| 000000 00000000 | Corporation | Salt Lake City, UT | 0000 | 00000 | 000000 - 000 | 00000 |
| 000000 | Corporation | Saint Louis, MO | 00 | 0000000000 |
Fusion Antibodies Patents
Fusion Antibodies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202303531-D0 | Antibodies and uses thereof | Pending | 10-Mar-2023 | ||
| GB-202206385-D0 | Method | Pending | 02-May-2022 | ||
| GB-202116704-D0 | Antibodies and uses thereof | Inactive | 19-Nov-2021 | ||
| GB-201905032-D0 | Antibody library and method | Inactive | 09-Apr-2019 | ||
| GB-201904754-D0 | Antibody library and method | Inactive | 04-Apr-2019 |
Fusion Antibodies Executive Team (7)
Fusion Antibodies Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adrian Kinkaid | Fusion Antibodies | Chief Executive Officer & Board Member | 000 0000 |
| Colin Walsh | Crescent Capital | Board Member | 000 0000 |
| Richard Buick Ph.D | Fusion Antibodies | Board Member & Executive | 000 0000 |
| Simon Douglas Ph.D | Self | Chairman | 000 0000 |
| Sonya Ferguson | Fusion Antibodies | Board Member | 000 0000 |
Fusion Antibodies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Fusion Antibodies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|